SAINT-PRIEST, France--(BUSINESS WIRE)--Regulatory News: Biom’up (Paris:BUP) (the "Company"), specializing in surgical hemostasis, has announced that the U.S. Food and Drug Administration (FDA) has ...
SAINT-PRIEST, FRANCE / ACCESSWIRE / April 15, 2019 / Biom'up SA (the "Company") (PARIS: BUP), specializing in surgical hemostasis, announces today first sales on the US market of its HEMOBLAST Bellows ...
Biom’up SA, specializing in surgical haemostasis, announced the first sales of its Hemoblast Bellows Laparoscopic Applicator in US market. The first kits have been shipped overseas from Saint-Priest ...
Biom’up, specializing in surgical hemostasis, has announced that the US Food and Drug Administration (FDA) has granted marketing approval for its Hemoblast Bellows Laparoscopic Applicator for all ...
The issuer is solely responsible for the content of this announcement. Biom'up provides 2019 guidance for HEMOBLAST TM Bellows global sales Biom'up provides full-year 2019 guidance for global sales of ...
SAINT-PRIEST, France--(BUSINESS WIRE)--Regulatory News: Biom’up SA (the “Company”) (Paris:BUP), specializing in surgical hemostasis, announces that following a hearing held on October 30, 2019, the ...
Biom'up announces first US sales in laparoscopy for HEMOBLAST(TM) Bellows and the signing of an exclusive distribution agreement for HEMOBLAST(TM) Bellows in Australia 15.04.2019 / 08:00 The issuer is ...
HEMOBLAST Bellows can be used with a specially designed 35 cm cannula in the United States in minimally-invasive surgeries FDA approval creates options for patients and surgeons across a broad ...
SAINT-PRIEST, FRANCE / ACCESSWIRE / April 15, 2019 / Biom'up SA (the "Company") (PARIS: BUP), specializing in surgical hemostasis, announces today first sales on the US market of its HEMOBLAST Bellows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback